These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35971573)

  • 1. Guselkumab as a switching strategy after anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis.
    Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Armario-Hita JC; Pérez-Gil A; Chinchay FV; Galán-Gutiérrez M
    Dermatol Ther; 2022 Oct; 35(10):e15760. PubMed ID: 35971573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guselkumab: Mid-term effectiveness, drug survival, and safety in real clinical practice.
    Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Armario-Hita JC; Pérez-Gil A; Galán-Gutiérrez M
    Dermatol Ther; 2021 Mar; 34(2):e14798. PubMed ID: 33484067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guselkumab dosing interval optimization in adult patients with moderate-to-severe psoriasis switching from ustekinumab.
    Ruiz-Villaverde R; Chinchay FV; Rodriguez-Fernandez-Freire L; Armario-Hita JC; Pérez-Gil A; Galán-Gutiérrez M
    Dermatol Ther; 2022 Nov; 35(11):e15835. PubMed ID: 36114755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study.
    Megna M; Potestio L; Ruggiero A; Camela E; Fabbrocini G
    J Dermatolog Treat; 2022 Aug; 33(5):2560-2564. PubMed ID: 35098859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence.
    Medina-Catalán D; Riera P; Pagès-Puigdemont N; Masip M; López-Ferrer A; Vilarrasa E; Puig L
    Int J Clin Pharm; 2022 Jun; 44(3):725-730. PubMed ID: 35380392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Super responders to guselkumab treatment in moderate-to-severe psoriasis: a real clinical practice pilot series.
    Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Armario-Hita JC; Pérez-Gil A; Galán-Gutiérrez M
    Int J Dermatol; 2022 Aug; 61(8):1029-1033. PubMed ID: 34731493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Super-Responders in Moderate-Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives.
    Ruiz-Villaverde R; Vasquez-Chinchay F; Rodriguez-Fernandez-Freire L; C Armario-Hita J; Pérez-Gil A; Galán-Gutiérrez M
    Life (Basel); 2022 Sep; 12(9):. PubMed ID: 36143449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brodalumab: Efficacy, safety, and survival in mid-term (52 weeks) on real clinical practice in Andalucia, Spain.
    Galan-Gutierrez M; Font-Ugalde P; Padilla L; Hernandez-Montoya C; Godoy D; Armario-Hita JC; Ruiz-Villaverde R
    Int J Dermatol; 2023 May; 62(5):700-706. PubMed ID: 36495585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risankizumab treatment in psoriasis patients who failed anti-IL17: A 52-week real-life study.
    Megna M; Potestio L; Ruggiero A; Camela E; Fabbrocini G
    Dermatol Ther; 2022 Jul; 35(7):e15524. PubMed ID: 35439341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year.
    Galluzzo M; Talamonti M; Bernardini N; Chiricozzi A; De Simone C; Bonifati C; Bruni P; Diotallevi F; Esposito M; Graceffa D; Hansel K; Loconsole F; Moretta G; Mugheddu C; Papini M; Richetta A; Skroza N; Atzori L; Fargnoli MC; Persechino S; Offidani A; Stingeni L; Peris K; Potenza C; Bianchi L
    Expert Opin Biol Ther; 2022 Dec; 22(12):1585-1592. PubMed ID: 35708257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
    Del Alcázar E; López-Ferrer A; Martínez-Doménech Á; Ruiz-Villaverde R; Llamas-Velasco MDM; Rocamora V; Julià M; Notario J; Fernández-Freire LR; Sahuquillo-Torralba A; Vidal D; Rivera R; Carretero G; Mateu A; de la Cueva P; Carrascosa JM
    Dermatol Ther; 2022 Feb; 35(2):e15231. PubMed ID: 34820971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of guselkumab in patients with moderate-to-severe plaque psoriasis: a retrospective study from China.
    Huang H; Liu H; Zhu Z; Wang W; Liang B; Tang H; Yang S; Sheng Y; Sun L; Zhang X
    Eur J Dermatol; 2024 Feb; 34(1):73-78. PubMed ID: 38557462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world effectiveness and safety of Guselkumab for the treatment of psoriasis: a 6-month prospective study in a series of psoriatic patients.
    Malara G; Trifirò C; Bartolotta A; Giofré C; D'Arrigo G; Testa A; De Lorenzo A; Tripepi G
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):406-412. PubMed ID: 33506930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study.
    Ruggiero A; Fabbrocini G; Cinelli E; Megna M
    Dermatol Ther; 2022 Jan; 35(1):e15214. PubMed ID: 34800070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study.
    Megna M; Tommasino N; Potestio L; Battista T; Ruggiero A; Noto M; Fabbrocini G; Genco L
    J Dermatolog Treat; 2022 Sep; 33(6):2813-2820. PubMed ID: 35603992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience.
    Bardazzi F; Viviani F; Merli Y; Di Lernia V; Peccerillo F; Conti A; Lasagni C; Tabanelli M; D'Adamio S; Di Nuzzo S; Cortellazzi C; Filippi F
    Expert Opin Biol Ther; 2022 Dec; 22(12):1561-1566. PubMed ID: 35388713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A real-life experience as a proof of Guselkumab effectiveness and safety in patients with moderate to severe psoriasis.
    Michelucci A; Manzo Margiotta F; Panduri S; Tonini A; Romanelli M; Morganti R; Janowska A; Dini V
    Dermatol Ther; 2022 Apr; 35(4):e15339. PubMed ID: 35088508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of risankizumab in psoriasis patients who failed anti-IL-17, anti-12/23 and/or anti IL-23: Preliminary data of a real-life 16-week retrospective study.
    Megna M; Fabbrocini G; Ruggiero A; Cinelli E
    Dermatol Ther; 2020 Nov; 33(6):e14144. PubMed ID: 32761740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study.
    Megna M; Ruggiero A; Martora F; Vallone Y; Guerrasio G; Potestio L
    J Clin Med; 2024 May; 13(9):. PubMed ID: 38731220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.